36 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Endocrinology & Metabolic Disorders Vide‪o‬ PeerVoice

    • Science
    • 5.0 • 1 Rating

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Let Their Feet Lead the Way: Tools for Early Identification of FOP

    Let Their Feet Lead the Way: Tools for Early Identification of FOP

    Visit https://www.peervoice.com/VRX860 to view the entire programme with slides. After completing “Let Their Feet Lead the Way: Tools for Early Identification of FOP”, participants will be able to: Recognize the key clinical features of fibrodysplasia ossificans progressiva (FOP); Explain the role of imaging and laboratory analysis for confirming the diagnosis of FOP; Apply best practices for recognition and referral of FOP to practice.

    • 22 min
    • video
    Stroke Prevention, Type 2 Diabetes, and GLP-1 Receptor Agonists: What Neurologists Need to Know

    Stroke Prevention, Type 2 Diabetes, and GLP-1 Receptor Agonists: What Neurologists Need to Know

    Visit https://www.peervoice.com/UWX860 to view the entire programme with slides. After completing “Stroke Prevention, Type 2 Diabetes, and GLP-1 Receptor Agonists: What Neurologists Need to Know”, participants will be able to: Explain the role of GLP-1 RAs in stroke prevention in type 2 diabetes (T2DM); Evaluate the cardiovascular outcomes data for GLP-1 RAs in terms of stroke prevention in patients with T2DM; and Apply optimal treatment plans for reducing the risk of stroke in patients with T2DM.

    • 46 min
    • video
    Modern Management of Chronic Kidney Disease: A Look to the Future

    Modern Management of Chronic Kidney Disease: A Look to the Future

    Visit https://www.peervoice.com/JTJ860 to view the entire programme with slides. After completing “Modern Management of Chronic Kidney Disease: A Look to the Future”, participants will be able to: Explain the rationale for novel therapies for the management of chronic kidney disease (CKD); Evaluate the safety and efficacy of recent clinical data for managing CKD, focusing on novel therapies; and Analyse the clinical implications of emerging evidence for managing CKD.

    • 11 min
    • video
    SGLT2 Inhibition for HF: Evidence From Virtual Scientific Sessions 2020

    SGLT2 Inhibition for HF: Evidence From Virtual Scientific Sessions 2020

    Visit https://www.peervoice.com/QTK860 to view the entire programme with slides. After completing “SGLT2 Inhibition for HF: Evidence From Virtual Scientific Sessions 2020”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with heart failure (HF); Analyse clinical evidence for safety and efficacy of medical therapy such as SGLT2 inhibitors in patients with HF; and Describe the potential clinical implications of novel strategies on outcomes in HF.

    • 12 min
    • video
    Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights of Kidney Week 2020

    Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights of Kidney Week 2020

    Visit https://www.peervoice.com/BSU860 to view the entire programme with slides. After completing “Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights of Kidney Week 2020”, participants will be able to: Describe key safety and efficacy data on SGLT2 inhibition for the management of chronic kidney disease (CKD); Summarise what the latest data on SGLT2 inhibition add to the current treatment algorithm for CKD; and Discuss the clinical implications of SGLT2 inhibition in the context of managing patients with CKD.

    • 11 min
    • video
    Novel Strategies for Chronic Kidney Disease: New Data, New Paradigm?

    Novel Strategies for Chronic Kidney Disease: New Data, New Paradigm?

    Visit https://www.peervoice.com/YPT860 to view the entire programme with slides. After completing “Novel Strategies for Chronic Kidney Disease: New Data, New Paradigm?”, participants will be able to: Summarise key finding from a published study evaluating an SGLT2 inhibitor for the management of CKD; Discuss the strengths and limitations of this study in light of current practices for the management of CKD; and Describe the impact of these data on clinical practice within the context of current and future treatment paradigms for CKD with or without diabetes.

    • 22 min

Customer Reviews

5.0 out of 5
1 Rating

1 Rating

小猪月亮 ,

peervoice

it is a brilliant software and website.
I love it.

Ligang Zhou.
Professor of Endocrinology

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerVoice